Updates

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com June 30, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/ Madam, Sub: Business Responsibility & Sustainability Report of the Company for the FY2026 Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the Business Responsibility and Sustainability Report (‘BRSR Report’) for the Financial Year 2025-26. The BRSR Report forms an integral part of the Integrated Annual Report of the Company for the Financial Year 2025-26. The BRSR Report is also available on the Company’s website and can be accessed at the following link: Business Responsibility and Sustainability Report This is for your information and records. Thanking you. Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer and Head-CSR BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT FY2025-26 KEY HIGHLIGHTS OF BRSR FY2025-26 Principle 1 Conduct and govern with integrity, and in a manner that is ethical, transparent and accountable a. 80.1% of our employees and 75.9% workers received periodic training on ethical conduct, aspects of human rights, skilling and wellbeing, and ESG goals and matters. b. No disciplinary action against Directors/KMPs/Employees/ Workers by any law enforcement agencies for charges of bribery/corruption c. No cases of fines, penalties, fees, or settlement amount paid in proceedings (by the entity or by directors/KMPs) with regulators, law enforcement agencies, or judicial institutions Principle 2 Provide goods and services in a manner that is sustainable and safe a. We conducted Life Cycle Assessment for 8 products (5 API’s, 3 formulations for Cradle-to-gate) and these have no significant social or environmental risks b. 100% of our inputs are sourced from suppliers who abide by our Third Party Code of Conduct c. 98% of our global waste is diverted from landfill to recycling / co-processing / reuse d. 92% of cold boxes are reused at CFA or stockist level Principle 3 Respect and promote the wellbeing of all employees, including those in value chains a. Permanent employees and workers are covered under health and accident insurance, and maternity and paternity benefits b. 91.9 % return to work rate and 90.5 % retention rate for our permanent employees post parental leave c. 97% employees and 77.5 % workers were provided skill upgradation training d. 72.4% employees and 59.6 % workers were provided health and safety measures training e. 96.7% of employees and 98.9% of workers have undergone performance and career development reviews f. Combined LTIFR per one mn-person hours worked is 0.04 Principle 4 Principle 5 Respect the interests of and be responsive to all Respect and promote human rights its stakeholders a. 76.2 % of employees were given training a. Comprehensive stakeholder engagement including on human rights a new double materiality assessment to understand b. 100% of our employees and permanent workers are their impact and financial materiality and stakeholder paid more than the minimum wage expectations to inform our ESG strategy c. Median remuneration of male and female employees b. Evolved process for considering feedback of the was ₹ 0.7 million and ₹ 0.88 million respectively stakeholders on economic, environment and social topics by the Board d. 100% of plant or offices were assessed for human rights issues c. Evolved process for engagement and support of the vulnerable and marginalised stakeholders group Principle 6 Principle 7 Respect and make efforts to protect and restore Influencing public and regulatory policy, in a the environment responsible and transparent manner a. 50% absolute reduction in scope 1&2 emissions from a. Associated with eight trade and industry chambers/ baseline year 2023 associations to foster dialogue on key policy issues b. 78% of electricity consumption through b. Advocated on regulatory changes regulatory changes, renewable power R&D and intellectual property protection, access and affordability, and counterfeit drugs c. 90,249 KL of harvested rainwater consumed c. No adverse order/action from regulatory authorities on d. 7.7 % decrease in reported Scope 3 emissions from anti-competitive conduct previous financial year Principle 8 Principle 9 Promote inclusive growth and equitable Engage with and provide value to the consumers development in a responsible manner a. 71.5% of input materials were sourced from within India a. 100% of our formulation products representing 89% of revenue carry information about safe and responsible b. Job creation in Rural, Semi-urban and Urban areas usage on product labelling and packaging was 6.5%, 8.5% and 8.7%, respectively, of total during the year b. No forced recalls, 17 voluntary recalls c. Positively impacted ~1,119,100 individuals through c. No consumer complaints on data privacy, advertising, CSR initiatives cyber-security, delivery of essential services, or restrictive or unfair trade practices d. No major service disruptions BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT SECTION A GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identity Number (CIN) of the Listed Entity L85195TG1984PLC004507 2. Name of the Listed Entity Dr. Reddy’s Laboratories Limited 3. Year of incorporation 1984 4. Registered office address 8-2-337, Road No. 3, Banjara Hills, Hyderabad – 500 034, Telangana, India 5. Corporate address 8-2-337, Road No. 3, Banjara Hills, Hyderabad – 500 034, Telangana, India 6. E-mail shares@drreddys.com 7. Telephone +91-40-49002900 8. Website http://www.drreddys.com 9. Financial year for which reporting is being done April 1, 2025 to March 31, 2026 10. Name of the Stock Exchange(s) where shares are listed a. BSE Limited b. National Stock Exchange of India Limited c. New York Stock Exchange, Inc d. NSE IFSC Ltd 11. Paid-up Capital INR 83,46,56,970 12. Name and contact details (telephone, email address) of Mr. K Randhir Singh the person who may be contacted in case of any queries on Company Secretary, Compliance Officer & Head-CSR the BRSR report 91-040-4900 2222 shares@drreddys.com 13. Reporting boundary The disclosure under BRSR is on consolidated basis unless otherwise specified at the respective section. 14. Name of assessment or assurance provider DNV Business Assurance India Private Limited (DNV) 15. Type of assessment or assurance obtained a. BRSR Core - Reasonable assurance b. Other selected BRSR indicators - Limited Assurance II. Products/services 16. Details of business activities (accounting for 90% of the turnover) S. Description of Main Activity Description of Business Activity % of Turnover of the entity 1. Pharmaceuticals Development, manufacturing & sale of pharmaceutical 100 products, and services 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. Product/Service NIC Code % of total turnover No. contributed 1. Development, manufacturing & sale of generic formulations including biosimilars and 21009 89 consumer healthcare 2. Development, manufacturing & sale of active pharmaceutical ingredients & custom 21009 10 pharmaceutical services III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of Total (Including R&D sites/operations) offices National 27 15 42 International 6 63 69 19. Markets served by the entity: a. Number of locations Locations Number National (No. of States and Union Territories) 36 International (No. of Countries) 87 b. What is the contribution of exports as a percentage of the total turnover of the entity? Out [Showing first 8,000 characters — download PDF for full document]